EVE Health Group Limited (EVE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, EVE Health Group Limited (EVE) has a cash flow conversion efficiency ratio of -0.242x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-907.94K ≈ $-642.42K USD) by net assets (AU$3.76 Million ≈ $2.66 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
EVE Health Group Limited - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how EVE Health Group Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read EVE liabilities breakdown for a breakdown of total debt and financial obligations.
EVE Health Group Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of EVE Health Group Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Peraso Inc
NASDAQ:PRSO
|
-0.430x |
|
Gafisa S.A
SA:GFSA3
|
-0.027x |
|
PREMIER1 Lithium Ltd
AU:PLC
|
-0.106x |
|
Lohilo Foods AB
ST:LOHILO
|
-0.017x |
|
Cambridge Technology Enterprises Limited
NSE:CTE
|
0.319x |
|
Syncona Limited
LSE:SYNC
|
0.006x |
|
Ansal Properties & Infrastructure Limited
NSE:ANSALAPI
|
-0.110x |
|
Blende Silver Corp
V:BAG
|
-0.006x |
Annual Cash Flow Conversion Efficiency for EVE Health Group Limited (2004–2025)
The table below shows the annual cash flow conversion efficiency of EVE Health Group Limited from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see EVE stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$3.55 Million ≈ $2.51 Million |
AU$-1.62 Million ≈ $-1.14 Million |
-0.455x | +49.72% |
| 2024-06-30 | AU$1.22 Million ≈ $866.05K |
AU$-1.11 Million ≈ $-783.25K |
-0.904x | -71.38% |
| 2023-06-30 | AU$3.12 Million ≈ $2.21 Million |
AU$-1.65 Million ≈ $-1.17 Million |
-0.528x | +3.00% |
| 2022-06-30 | AU$6.93 Million ≈ $4.91 Million |
AU$-3.77 Million ≈ $-2.67 Million |
-0.544x | -146.98% |
| 2021-06-30 | AU$10.19 Million ≈ $7.21 Million |
AU$-2.24 Million ≈ $-1.59 Million |
-0.220x | +9.31% |
| 2020-06-30 | AU$12.99 Million ≈ $9.19 Million |
AU$-3.16 Million ≈ $-2.23 Million |
-0.243x | -32.63% |
| 2019-06-30 | AU$5.85 Million ≈ $4.14 Million |
AU$-1.07 Million ≈ $-757.90K |
-0.183x | -67.12% |
| 2018-06-30 | AU$7.38 Million ≈ $5.22 Million |
AU$-808.76K ≈ $-572.25K |
-0.110x | +45.55% |
| 2017-06-30 | AU$2.78 Million ≈ $1.97 Million |
AU$-558.99K ≈ $-395.52K |
-0.201x | +45.42% |
| 2016-06-30 | AU$1.75 Million ≈ $1.24 Million |
AU$-645.76K ≈ $-456.92K |
-0.369x | -305.44% |
| 2015-06-30 | AU$2.64 Million ≈ $1.87 Million |
AU$-240.46K ≈ $-170.14K |
-0.091x | -368.93% |
| 2014-06-30 | AU$8.11 Million ≈ $5.74 Million |
AU$-157.19K ≈ $-111.23K |
-0.019x | +79.66% |
| 2013-06-30 | AU$8.18 Million ≈ $5.79 Million |
AU$-779.82K ≈ $-551.77K |
-0.095x | -39.15% |
| 2012-06-30 | AU$23.04 Million ≈ $16.30 Million |
AU$-1.58 Million ≈ $-1.12 Million |
-0.069x | +64.89% |
| 2011-06-30 | AU$25.64 Million ≈ $18.14 Million |
AU$-5.00 Million ≈ $-3.54 Million |
-0.195x | -117.47% |
| 2010-06-30 | AU$25.15 Million ≈ $17.79 Million |
AU$-2.26 Million ≈ $-1.60 Million |
-0.090x | +29.17% |
| 2009-06-30 | AU$22.93 Million ≈ $16.23 Million |
AU$-2.91 Million ≈ $-2.06 Million |
-0.127x | -29.01% |
| 2008-06-30 | AU$25.64 Million ≈ $18.14 Million |
AU$-2.52 Million ≈ $-1.78 Million |
-0.098x | -34.67% |
| 2007-06-30 | AU$18.78 Million ≈ $13.29 Million |
AU$-1.37 Million ≈ $-969.08K |
-0.073x | -104.92% |
| 2006-06-30 | AU$5.98 Million ≈ $4.23 Million |
AU$-212.78K ≈ $-150.56K |
-0.036x | +46.18% |
| 2005-06-30 | AU$2.22 Million ≈ $1.57 Million |
AU$-146.87K ≈ $-103.92K |
-0.066x | +70.17% |
| 2004-06-30 | AU$251.35K ≈ $177.84K |
AU$-55.71K ≈ $-39.42K |
-0.222x | -- |
About EVE Health Group Limited
EVE Health Group Limited, together with its subsidiaries, engages in the development, retail, and commercialization of health and wellness, and pharmaceutical products. The company lead product is Dyspro, a proprietary pharmaceutical-grade formulation to address dysmenorrhea (menstrual pain); and Libbo, a proprietary pharmaceutical-grade oral dissolving film formulation for the treatment of erect… Read more